A Systemic Immune Inflammation Index and PD-L1 (SP142) Expression as a Potential Combined Biomarker of the Clinical Benefit of Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
Conclusions: The combined SII-SP142 biomarker can be readily and universally obtained at a low cost in clinical practice, without requiring advanced genomics technology or specialized expertise. Although further studies are needed to confirm that the combined SII-SP142 biomarker is widely applicable, it should help clinicians to identify the best patients for combined chemotherapy with atezolizumab in ES-SCLC.PMID:38592329 | PMC:PMC10932321 | DOI:10.3390/jcm13051521
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Jong-Min Baek Hyungkeun Cha Yeonsook Moon Lucia Kim Seung Min Kwak Eun Sun Park Hae-Seong Nam Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Lung Cancer | Small Cell Lung Cancer | Study